Japanese SearchCareersSitemapContact

NCRM has been working on Clinically usable stem cells, progenitor cells, precursor cells and autologous mature cells with regenerative capability. In this regard, the major areas of focus have been finding out ways and technologies to grow cells and engineer tissues in the laboratory (i) without animal or biological protein (ii) with a longer in situ life span upon implantation, (iii) without causes of concern with regard to teratogenicity or mutation etc. 

In the Cell culture and Tissue engineering arena we have technological collaborations and confidentiality agreements for with a couple of Japanese institutes both private and public.

In Cancer Biology & Immunotherapy


In the front of Cancer biology Dr Terunuma Hiroshi (formerly with Tokyo Medical & Dental University, Japan) has been working for more than two decades on Cancer cells, Cancer biology and the body's immune mechanism against Cancer as well as ways to tackle the cancer phenomenon using the body's own immune system.

He has also pioneered in certain technology and processing methodology by which cancer killing body's cells such as Natural Killer cells and Anti-Tumor Lymphocytes could be cultured outside the body, which when reinfused back to the patient, kill the cancer cells effectively. He has established the Biotherapy Institute through which they have successfully administered Autologous Immune Enhancement Therapy (AIET) more than 1000 patients with very good results. Further in their research, they are also having several projects in their institute on Cytotoxic T Lymphocytes and Anti-Viral activity of body's immune system, which when successful would be of much help to the HIV patients.

In 3D Cell Culture & Tissue engineering


The research on the three dimensional cell culture for Regenerative Medicine and related issues started in 1988 by Prof. Yuichi Mori of Waseda University. They started with finding a suitable non-biological substrate for preserving, isolating and multiplying cells of various nature in the laboratory. In 1998 they could achieve a break through in their research with the Japanese government’s support, to arrive at certain technological processes and a totally non-biological Thermogelation polymer called “Mebiol Gel” which is capable of allowing specific cells/ tissues including even embryonic stem cells to grow in the laboratory as well as prolong their viability in the body.

In 1998, this was validated by another polymer engineer Dr Hiroshi Yoshioka. Then institutes in Japan (St Marianna University- Prof. S. Kubota, Tokyo University- Dr. Hishikawa, Institute of Infectious Diseases- Dr Suzuki, Jikei University Hospital- Dr Murayama), India (Sankara nethralaya-Dr HN. Madhavan, Centre For liver research and diagnostics- Dr CM Habibullah) USA (Harvard Medical School- Dr. Koji Kojima) joined this research following which we have been successful the following accomplishments.


In Nanotechnology & Tissue engineering


The nanotechnology in biology, especially the nano coated surfaces for cell culture, tissue engineering, nano shell contained drugs and nano particle mixed ionic vicinity for membrane like as well as 3D growth of cells with easy separation have a lot of potentials in Regenerative Medicine. NCRM has been working jointly with a couple of Japanese institutes based on a Confidentiality agreement to develop such technologies be taken to clinical application through standardized procedures and protocols over another 5 to 10 years.


As human cells and tissues behave differently in vitro that too with different surfaces and adherence properties, optimization of media, surfaces, substrates have to be combined to create a suitable condition for each cell or tissue to grow its best without losing their phenotype and genotype and with parameters acceptable for clinical application has been a challenge, which we hope could be overcome to a significant extent in various types of cells using the Nanotechnology and the hope has been our driving force with this research.



Accomplishments in the Research activities

1.      Embryonic stem cells could be grown without animal feeder layers and can be isolated without enzymatic damage. They can also be kept in an undifferentiated condition while grown.

2.      Viability of various cells and tissues we are able to prolong up to 220% compared to the conventional cell culture methods, with our materials and technology. In this manner transportation of isolated corneal endothelial cells in indian conditions at room temperature and subsequent expansion of the precursors has been accomplished.

3.      Adult stem cells like Corneal limbal stem cells, Foetal hepatic progenitors, Bone marrow stem cells can be grown without biological feeder layers or human amniotic membrane.

4.      Three dimensional growth of the cells and tissues has been made possible with various cells; especially cancer cells and cell lines

5.      In-situ (in the body) growth and expansion for healing of osteocytes and hepatocytes we are able to assist with our materials and technology.

6.    Anti-cancer T-lymphocyte activation and expansion in the laboratory for clinical treatment has been made possible

7.   Natural Killer cells expansion has been made feasible in the in vitro conditions.

8.    We can avoid unwanted cells to hamper the cells of interest under cultivation especially the growth of fibroblasts could be controlled.

9.   Various viruses could be isolated for research work on them to develop anti viral agents.

10.  Sustained release of drugs is possible in a much smoother and optimal dosage level than before using specifically tailored polymer substrate, which can be implanted in the body

11. Transportation of corneal endothelial buttons in varying climatic conditions and their in vitro expansion has been accomplished which we hope would help treat corneal endothelial diseases


Accomplishments with the Clinical Applications

1. For the first time in India we have started Autologous Immune Enhancement Therapy for cancer

2. Clinical trials are under planning for Corneal Epithelial Disorders through our collaborative institutes

3. Foetal Hepatocyte based therapy as a clinical trial are under planning for acute liver failure in our collaborating institute.

4. Stem cell based treatments have been started


With the above achievements till date, NCRM has brought the technology to India and has started collaborating with the

premier health care institutes in India in respective specialties to transfer the technology from bench (Lab) to bedside (clinical application)


*"Nichi" stands for Japan and "In" stands for India. This institute started on an Indo-Japan collaboration now has spreaded further with global alliances
    © NCRM. All right reserved.                                                                                                                                                                                          Disclaimer